Skip Navigation



European Heart Journal Advance Access published online on June 27, 2007
European Heart Journal, doi:10.1093/eurheartj/ehm259
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
28/15/1795    most recent
ehm259v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kaden, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaden, J. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Towards medical therapy of calcific aortic stenosis—lessons from molecular biology

Jens J. Kaden*

I Medizinische Klinik, Universitätsklinikum Mannheim, Theodor-Kutzer-Ufer 1–3, D-68167 Mannheim, Germany

* Corresponding author. Tel: +49 621 383 3821; fax: +49 621 383 2204. E-mail address: jens.kaden@med.ma.uni-heidelberg.de

This editorial refers to ‘Increased expression of profibrotic neutral endopeptidase and bradykinin type 1 receptors in stenotic aortic valves’ by S. Helske et al., doi:10.1093/eurheartj/ehm129

The first 10% of the full text of this article appears below.

Calcific aortic stenosis, with a prevalence of 3–9%, is the most frequent heart valve disease and the main reason for valve replacement in patients over 60 years of age.1 Histopathologically, sclerosis of the aortic valve is defined as fibrous thickening and calcification of the valve cusps.2 For many years, these changes were thought to be caused by passive calcium precipitation within the valve. However, there is increasing evidence that the development and progression of calcific aortic stenosis may be triggered by underlying genetic and acquired risk factors.3 Early . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Increased expression of profibrotic neutral endopeptidase and bradykinin type 1 receptors in stenotic aortic valves
Satu Helske, Mika Laine, Markku Kupari, Jyri Lommi, Heikki Turto, Laura Nurmi, Ilkka Tikkanen, Kalervo Werkkala, Ken A. Lindstedt, and Petri T. Kovanen
EHJ 2007 28: 1894-1903. [Abstract] [FREE Full Text]  



This article has been cited by other articles:


Home page
 Eur. J. Cardiothorac. Surg.Home page
A. Parolari, C. Loardi, L. Mussoni, L. Cavallotti, M. Camera, P. Biglioli, E. Tremoli, and F. Alamanni
Nonrheumatic calcific aortic stenosis: an overview from basic science to pharmacological prevention
Eur. J. Cardiothorac. Surg., March 1, 2009; 35(3): 493 - 504.
[Abstract] [Full Text] [PDF]